-
CTIC broke support of .37 today next support is .33 Resistance .37 and .43
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Cell Therapeutics, Inc. Pixantrone Now Available in Europe on a Named-Patient Basis
Press Release Source: Cell Therapeutics, Inc.
Pixantrone Now Available in Europe on a Named-Patient Basis
On Tuesday May 5, 2009, 1:30 am EDT
SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe.
Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.
"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI.
"We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food & Drug Administration this quarter."
"Our experience with pixantrone has been positive with patients achieving a complete response where such a result was not achievable with other treatments," said Prof. Pier Luigi Zinzani, M.D., Institute of Hematology and Oncology, University of Bologna.
"I am pleased that it is now available on a named-patient basis as it has the potential to address a significant unmet need in this heavily pretreated patient population."
A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In Europe, under the named-patient program the drug is most often purchased through the national health system.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here
-
 Pixantrone Now Available in Europe on a Named-Patient Basis
Pixantrone Now Available in Europe on a Named-Patient Basis
Tuesday , May 05, 2009 01:30ET 
KNOBIAS: RAiDAR Story
Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program
SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.
"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI. "We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food & Drug Administration this quarter."
"Our experience with pixantrone has been positive with patients achieving a complete response where such a result was not achievable with other treatments," said Prof. Pier Luigi Zinzani, M.D., Institute of Hematology and Oncology, University of Bologna. "I am pleased that it is now available on a named-patient basis as it has the potential to address a significant unmet need in this heavily pretreated patient population."
A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In Europe, under the named-patient program the drug is most often purchased through the national health system.
Contact Information for Program:
Licensed healthcare professionals in Europe treating individual patients with relapsing or refractory aggressive non-Hodgkin's lymphoma interested in pixantrone should contact:
IDIS Limited
Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com
Additionally, more information can be found at
Pixantrone access in Europe through a named patient program (compassionate use) for patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL) - Cell Therapeutics, Inc.
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.
About IDIS
IDIS is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. For more information on IDIS please visit their website at IDIS - Managing World Medicines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
Investors, Ed Bell
206-272-4345
Lindsey Jesch Logan
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Important Co. News
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
-
 CTIC - News - Pixantrone Now Available in Europe on a Named-Patient Basis
Pixantrone Now Available in Europe on a Named-Patient Basis
Tuesday , May 05, 2009 01:30ET
KNOBIAS: RAiDAR Story
Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program
SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.
"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI. "We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food & Drug Administration this quarter."
"Our experience with pixantrone has been positive with patients achieving a complete response where such a result was not achievable with other treatments," said Prof. Pier Luigi Zinzani, M.D., Institute of Hematology and Oncology, University of Bologna. "I am pleased that it is now available on a named-patient basis as it has the potential to address a significant unmet need in this heavily pretreated patient population."
A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In Europe, under the named-patient program the drug is most often purchased through the national health system.
Contact Information for Program:
Licensed healthcare professionals in Europe treating individual patients with relapsing or refractory aggressive non-Hodgkin's lymphoma interested in pixantrone should contact:
IDIS Limited
Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com
Additionally, more information can be found at
Pixantrone access in Europe through a named patient program (compassionate use) for patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL) - Cell Therapeutics, Inc.
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.
About IDIS
IDIS is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. For more information on IDIS please visit their website at IDIS - Managing World Medicines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
SOURCE Cell Therapeutics, Inc.
Contacts:
Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com
Investors, Ed Bell
206-272-4345
Lindsey Jesch Logan
206-272-4347
fax
206-272-4434
invest@ctiseattle.com
all of Cell Therapeutics, Inc.
Public Companies Associated with this story:
CTIC
Knobias Subject Codes Associated with this story:
Important Co. News
Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com
KNOBIAS: RAiDAR Story
ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.
-
CTIC blowing up still
Great job to all that got into CTIC from the other day, now up over 80% from the chat room call. Make sure you join us in the chat room at Stock Hideout Chat during market hours Monday - Friday
 Originally Posted by chuck44l
CTIC broke support of .37 today next support is .33 Resistance .37 and .43
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here
-
CTIC TABLE: Confirmed Earnings Expected Thursday, May 7
CTIC TABLE: Confirmed Earnings Expected Thursday, May 7
Wednesday, May 06, 2009 06:35ET
KNOBIAS: RAiDAR Story
The following companies are scheduled to report their quarterly earnings on Thursday, May 7, 2009 according to a previous announcement:
-
CTIC TABLE: Confirmed Earnings Expected Thursday, May 7
CTIC TABLE: Confirmed Earnings Expected Thursday, May 7
Wednesday, May 06, 2009 06:35ET
KNOBIAS: RAiDAR Story
CTIC Cell Therapeutics Inc Q1 BMO $1.27M -0.31
The following companies are scheduled to report their quarterly earnings on Thursday, May 7, 2009 according to a previous announcement:
-
CTIC News
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
On Tuesday June 2, 2009, 1:30 am EDT
Buzz up! Print.Related:Cell Therapeutics, Inc.
Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy
Related Quotes
Symbol Price Change
CTIC 2.10 0.00
{"s" : "ctic","k" : "c10,l10,p20,t10","o" : "","j" : ""} ORLANDO, June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the poster and discussion session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American Society of Clinical Oncology ("ASCO") Annual Meeting, new subgroup analysis data were reviewed from the phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") demonstrating the effectiveness of pixantrone as therapy in patients with aggressive non-Hodgkin's lymphoma ("NHL") for whom anthracycline and related drugs are typically not to be used due to a high risk of cardiac toxicity, including cardiac failure.
Twenty-five of the 70 patients in the PIX 301 EXTEND trial had received prior cumulative doxorubicin doses in excess of the standard 300 mg/m2 associated with six cycles of first line CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. The median prior exposure of these patients, most of whom had received an anthracycline as part of a salvage regimen, was 386 mg/m2 (with a range of 306 mg/m2 to 778 mg/m2). Following treatment with pixantrone, ten of these 25 patients (40%) achieved a confirmed complete remission ("CR"), unconfirmed remission ("CRu") or partial remission ("PR") (CR=2, CRu= 5, 28%; PR=3, 12%) The lifetime cumulative doxorubicin equivalent dose following pixantrone was 579 mg/m2 (with a range of 361 mg/m2 to 1003 mg/m2). No patient developed a severe reduction (>=20%) in left ventricular ejection fraction (LVEF) and only one patient developed congestive heart failure (CHF). The total cumulative doxorubicin equivalent exposure per treatment cycle for all 68 patients treated with pixantrone is noted in the table below:
Treatment Cycle No. of Patients Pixantrone Lifetime
Treatment Cumulative
Cumulative Dose Dose
Median mg/m2 Median mg/m2
1 68 74 365.2
2 54 148 430.2
3 43 209 498.1
4 36 275 571.8
5 25 356 631.5
6 22 427 695.0
Lifetime doses of doxorubicin of over 550 mg/m2 are associated with a high incidence of CHF if the cumulative dose levels were solely with a standard anthracycline.
An additional new subgroup analysis was highlighted by the ASCO discussant, which demonstrated the clinical benefit associated with achieving a CR or CRu with pixantrone. On an intent-to-treat basis, patients achieving a CR/CRu on the pixantrone treatment arm (n=14) had a significant increase in the duration of remission compared with the four patients who achieved a CRu with standard chemotherapy (7 months vs. 3.5 months, p=0.03, HR=0.279; a hazard ratio of less than one indicates a decreased risk of disease progression and a p-value of less than 0.05 indicates statistical significance).
An analysis was also reported that evaluated the effect of prior rituximab therapy on response rates. In the 38 patients who received pixantrone following prior treatment with rituximab, 12 patients (32%) achieved a CR/CRu/PR of which six patients (16%) achieved a CR/CRu. In the comparator arm, the response rate was seven out of 39 patients (18%) with three CRu.
The discussant noted that overall response rates of 30% in this population of patients would represent a significant advance in the treatment of aggressive NHL and commented that that while numerically higher, the overall incidence of cardiac events were lower than expected in this patient group with substantial prior doxorubicin exposure reflected by no significant change in ejection fraction from baseline to end of treatment.
"This data demonstrates that pixantrone can induce durable complete remissions not only in patients previously treated with standard front-line doxorubicin, but even in patients who received an anthracycline as part of a salvage regimen. Resistance to rituximab was not associated with resistance to pixantrone. In patients with high cumulative prior doxorubicin exposure, the frequency of severe cardiac toxicity following up to six cycles of additional pixantrone was lower than would be expected based on historical comparisons to studies of doxorubicin," said James A. Bianco, M.D., Chief Executive Officer of CTI. "We are pleased with these results as they underscore the potential for pixantrone in this difficult to treat patient population for whom few options exist."
About the PIX301 EXTEND Trial
The PIX 301 EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.
CTI previously announced that its pivotal phase III EXTEND (PIX 301) trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14 out of 70 patients (20.0%) for the pixantrone arm compared to four out of 70 patients (5.7%) for the standard chemotherapy arm, p=0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission.
The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.
The ASCO poster is available at Investor Updates - Cell Therapeutics, Inc..
In April 2009, CTI began a rolling submission of a New Drug Application (the "NDA") with the U.S. Food and Drug Administration (the "FDA") for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.
Pixantrone is also now available in Europe on a named patient basis.
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..
Sign up for email alerts and get RSS feeds at our Web site, Investors - Cell Therapeutics, Inc. - 2009 News Releases
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors
Medical Information Contact:
T: 800.715.0944
E: info@askarm.com
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here
-
Good chart...Get ready for news this week!
Last edited by toxicity; 06-22-2009 at 01:58 PM.
-
Onward & Upward
Great call as we got news this week with pix submission & priority review.
Looking for approval in the 4th quarter.
Chart still looks great. ADX, MACD, RSI, MFI, Stochastics, all heading in the right direction.
As ZZ Top says, "She's got legs!"
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks